NO20010044D0 - Use of texapyrins in macrophage-mediated diseases - Google Patents

Use of texapyrins in macrophage-mediated diseases

Info

Publication number
NO20010044D0
NO20010044D0 NO20010044A NO20010044A NO20010044D0 NO 20010044 D0 NO20010044 D0 NO 20010044D0 NO 20010044 A NO20010044 A NO 20010044A NO 20010044 A NO20010044 A NO 20010044A NO 20010044 D0 NO20010044 D0 NO 20010044D0
Authority
NO
Norway
Prior art keywords
macrophage
texapyrins
mediated diseases
texaphyrins
subject
Prior art date
Application number
NO20010044A
Other languages
Norwegian (no)
Other versions
NO20010044L (en
Inventor
Kathryn W Woodburn
Stuart W Young
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of NO20010044D0 publication Critical patent/NO20010044D0/en
Publication of NO20010044L publication Critical patent/NO20010044L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods for treating disease of a subject in need thereof by sensitizing the effects of a co-therapeutic agent in macrophages. The method comprises administering a texaphyrin and a co-therapeutic agent to the subject. Texaphyrins are provided for enhancing the cytotoxicity of therapeutic agents in macrophage-mediated disease since texaphyrins have been shown to accumulate in macrophage.
NO20010044A 1998-07-06 2001-01-04 Use of texaphyrins in macrophage-mediated diseases NO20010044L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11050998A 1998-07-06 1998-07-06
PCT/US1999/015199 WO2000001414A1 (en) 1998-07-06 1999-07-06 Use of texaphyrins in macrophage-mediated disease

Publications (2)

Publication Number Publication Date
NO20010044D0 true NO20010044D0 (en) 2001-01-04
NO20010044L NO20010044L (en) 2001-03-01

Family

ID=22333401

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010044A NO20010044L (en) 1998-07-06 2001-01-04 Use of texaphyrins in macrophage-mediated diseases

Country Status (8)

Country Link
EP (1) EP1094840A1 (en)
JP (1) JP2002519390A (en)
KR (1) KR20010079498A (en)
AR (1) AR019226A1 (en)
AU (1) AU4860899A (en)
CA (1) CA2336134A1 (en)
NO (1) NO20010044L (en)
WO (1) WO2000001414A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6163988A (en) * 1995-05-17 2000-12-26 Rockland, Inc. Assembly connectable to an operating arm of a machine for performing work functions
RU2106146C1 (en) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Means to inhibit tumor growth
WO2001032210A2 (en) 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US7579338B2 (en) 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
JP2003012547A (en) * 2001-06-27 2003-01-15 Meiji Seika Kaisha Ltd Diagnostic and therapeutic agent for insulin dependent diabetes mellitus
CN103405769A (en) * 2013-03-07 2013-11-27 北京亿仁赛博医疗科技研发中心有限公司 Application of photosensitizer to preparation of virus inactivated medicines for treating diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy

Also Published As

Publication number Publication date
AU4860899A (en) 2000-01-24
CA2336134A1 (en) 2000-01-13
NO20010044L (en) 2001-03-01
EP1094840A1 (en) 2001-05-02
WO2000001414A1 (en) 2000-01-13
JP2002519390A (en) 2002-07-02
AR019226A1 (en) 2001-12-26
KR20010079498A (en) 2001-08-22

Similar Documents

Publication Publication Date Title
NO993393D0 (en) Photochemical therapeutic mixtures
ATE319447T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING CLAVULANIC ACID OR DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DK1296652T3 (en) Topical pharmaceutical formulations and treatment methods
YU37602A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IS4972A (en) Use of the chelating agent clioquinol in the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
DE60037394D1 (en) USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS IN CANCER THERAPY
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
CY1108629T1 (en) Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart
EP1514105A4 (en) Methods of modulating tubulin deacetylase activity
NO20050718L (en) Topical treatment of skin diseases
ATE197670T1 (en) PARENTERAL BUSULFAN FOR THE TREATMENT OF MALIGNANT DISEASES
ID27576A (en) USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES
NO20010044D0 (en) Use of texapyrins in macrophage-mediated diseases
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
PT900563E (en) PRODUCTION OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF EDEMA AND VENOUS DISEASES
ID23528A (en) THERAPEUTIC TREATMENT FOR SKIN DISORDERS
DK0773782T3 (en) Terpene derivatives (sarcodictyins) use as antitumor agents
SE9902597D0 (en) New use
CY1106702T1 (en) USE OF A COMBINATION OF A PURINE AND A NITROGEN MONOXIDE DONATOR FOR THE PREVENTION OR TREATMENT OF BENEFITS OF BENEFITS
DE60216292D1 (en) CALCIUM TRIFLUORACETATE WITH CYTOTOXIC EFFECT
HRP20050281A2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
NO984196L (en) Procedure for the treatment of substance abuse
DE69635282D1 (en) TREATMENT OF EXCESSIVE AGGRESSIVENESS WITH OLANZAPINE
RU94024337A (en) Antimetastatic agent

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application